Skip to main content

Advertisement

SpringerLink
Log in

Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the efficacy and security of conbercept and ranibizumab combined with trabeculectomy and panretinal photocoagulation for neovascular glaucoma (NVG).

Methods

One hundred and sixty patients with NVG were randomly divided into a conbercept group comprised of 80 patients and a ranibizumab group comprised of 80 patients. The postoperative and preoperative visual acuities, intraocular pressures frequency of anti-glaucoma medications, and surgical complications were recorded. The expressions of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (FLT-1), and placenta-like growth factor (PLGF) in the aqueous humor were determined using an enzyme-linked immunosorbent assay. Examining the fundus and obtaining photographs used indirect ophthalmoscopy. Kaplan–Meier and log-rank analyses estimated the success rates.

Results

All patient follow-up periods were at 1 year. The differences observed in IOP and the frequencies of anti-glaucoma medications at various follow-up time points were not statistically significant (all P > 0.05). The differences observed in both the group visual acuities at various follow-up time points were not statistically significant (P > 0.05). Rates of surgery complications were 18.75% and 25.00% in the conbercept group and ranibizumab group, respectively. The expressions of VEGF, FLT-1, and PLGF significantly decreased (all P < 0.05). The recurrence percentages were 30.00% and 36.25% after conbercept and ranibizumab treatment, respectively.

Conclusion

The conbercept effects were similar with that of ranibizumab. Intravitreal injection of conbercept was effective for NVG treatment, which provides a new therapeutic drug for NVG treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data of the current study are available from the corresponding author on reasonable request.

References

  1. Kwon J-w, Jee D, La TY (2017) Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. Medicine 96(10):e6263. https://doi.org/10.1097/md.0000000000006263

    Article  PubMed  PubMed Central  Google Scholar 

  2. Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, Leite A, Felix JP, Torigoe M, Diniz-Filho A (2016) Neovascular glaucoma: a review. Int J Retina Vitreous 2(1):26

    Article  Google Scholar 

  3. Shi L, Yang J, Lin J (2019) What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study. BMC Ophthalmol 19(1):128

    Article  Google Scholar 

  4. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K (2013) Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev 10(10):CD007920

    Google Scholar 

  5. Wu AL, Wu WC (2018) Anti-VEGF for ROP and Pediatric Retinal Diseases. Asia Pac J Ophthalmol 7(3):145–151. https://doi.org/10.22608/apo.201837

    CAS  Google Scholar 

  6. Sun Y, Liang Y, Zhou P, Wu H, Hou X, Ren Z, Li X, Zhao M (2016) Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. Bmc Ophthalmol 16(1):150

    Article  Google Scholar 

  7. Nakatake S, Yoshida S, Nakao S, Arita R, Yasuda M, Kita T, Enaida H, Ohshima Y, Ishibashi T (2014) Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis. BMC Ophthalmol 14(1):55

    Article  Google Scholar 

  8. Alkawas AA, Shahien EA, Hussein AM (2010) Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma 19(9):622–626

    Article  Google Scholar 

  9. Su L, Ren X, Wei H, Zhao L, Zhang X, Liu J, Su C, Tan L, Li X (2015) Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy. Retina 36(5):938–943

    Article  Google Scholar 

  10. Kowanetz M, Ferrara N (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res An Off J Am Assoc Cancer Res 12(17):5018–5022. https://doi.org/10.1158/1078-0432.CCR-06-1520

    Article  CAS  Google Scholar 

  11. Takano N, Sarfraz Y, Gilkes DM, Chaturvedi P, Xiang L, Suematsu M, Zagzag D, Semenza GL (2014) Decreased expression of cystathionine β-synthase promotes glioma tumorigenesis. Mol Cancer Res 12(10):1398–1406. https://doi.org/10.1158/1541-7786.Mcr-14-0184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhou M, Chen S, Wang W, Huang W, Cheng B, Ding X, Zhang X (2013) Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest Opthalmol Vis Sci 54(6):3874–3879

    Article  CAS  Google Scholar 

  13. Hayreh SS (2007) Neovascular glaucoma. Prog Retinal Eye Res 26(5):470–485

    Article  Google Scholar 

  14. Horsley MB, Kahook MY (2010) Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 21(2):112–117

    Article  Google Scholar 

  15. Silva Paula J, Jorge R, Alves Costa R, Rodrigues MDLV, Scott IU (1900) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84(4):556–557

    Article  Google Scholar 

  16. Elmekawey H, Khafagy A (2014) Intracameral ranibizumab and subsequent mitomycin C augmented trabeculectomy in neovascular glaucoma. J Glaucoma 23(7):437–440

    Article  Google Scholar 

  17. Kitnarong N, Sriyakul C, Chinwattanakul S (2015) A prospective study to evaluate intravitreous ranibizumab as adjunctive treatment for trabeculectomy in neovascular glaucoma. Ophthalmol Ther 4(1):33–41

    Article  Google Scholar 

  18. Sun J, Li B, Jia Z, Zhang A, Wang G, Chen Z, Shang Z, Zhang C, Cui J, Yang W (2018) RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway. J Neurooncol 140(1):15–26. https://doi.org/10.1007/s11060-018-2927-0

    Article  CAS  PubMed  Google Scholar 

  19. Chen S, Zhou M, Wang W, Wu H, Zhang X (2015) Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes. Acta Ophthalmol 93(7):e556–e560

    Article  CAS  Google Scholar 

  20. Azimi G, Ranjbaran F, Arsang-Jang S, Ghafouri-Fard S, Mazdeh M, Sayad A, Taheri M (2020) Upregulation of VEGF-A and correlation between VEGF-A and FLT-1 expressions in Iranian multiple sclerosis patients. Neurol Sci. https://doi.org/10.1007/s10072-019-04234-2

    Article  PubMed  Google Scholar 

  21. Raikwar NS, Liu KZ, Thomas CP (2013) Protein kinase C regulates FLT1 abundance and stimulates its cleavage in vascular endothelial cells with the release of a soluble PlGF/VEGF antagonist. Exp Cell Res 319(17):2578–2587

    Article  CAS  Google Scholar 

  22. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161(2):851–858. https://doi.org/10.1016/0006-291x(89)92678-8

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The authors declare that they have no funding.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Ningbo Eye Hospital, No. 599 Beimingcheng Road, Yinzhou District, Ningbo, 315000, Zhejiang Province, China

    Xiaohong Guo, Yuwen Wang, Liangyan Yang, Pengyun Wang, Kan Chen, Lei Zhou & Yue Wu

Authors
  1. Xiaohong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuwen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liangyan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pengyun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yue Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yue Wu.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Consent to participate

All patients were informed of the procedure and informed consent was obtained.

Ethical approval

This study was conducted the principles of the Declaration of Helsinki and approved by the institutional review board of Ningbo Eye Hospital.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, X., Wang, Y., Yang, L. et al. Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma. Int Ophthalmol 41, 2869–2877 (2021). https://doi.org/10.1007/s10792-021-01846-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-021-01846-6

Keywords

Search

Navigation